POSTER SESSION II: DISEASE-SPECIFIC STUDIES

Diabetes/Endocrine Disorders – Clinical Outcome Studies

PDB1 TREATMENT PATTERNS AND OUTCOMES AMONG OLDER EXENATIDE BI-Daily USERS COMPARED TO INSULIN GLARGINE USERS

Gaebel JA1, Schultz J2, Blickensderfer A3, Wrenten M4, Riedel A5, Harley C6
1Amylin Pharmaceuticals, Inc., San Diego, CA, USA, 2University of Minnesota, Duluth, MN, USA, 3Amylin Pharmaceuticals, Inc., Chesterfield, MO, USA, 4St Innovus, Eden Prairie, MN, USA, 5St Innovus, Palo Alto, CA, USA

OBJECTIVES: We evaluated treatment patterns, hypoglycemic events, glycemic control and medical costs for patients ~60y with type 2 diabetes mellitus (T2DM) initially initiating treatment on exenatide BID (ExBiD) or insulin glargine (IG). METHODS: Medical, pharmacy and lab data for commercial and Medicare Advantage enrollees were obtained from administrative claims from a large, national health plan. Subjects were identified from May 2005 to Dec 2008 with 6-mo baseline and 12-mo follow-up periods. Subjects with any insulin treatment during baseline were excluded. Propensity score (PS) matching (1:1) of ExBiD and IG subjects was used to create balanced cohorts. Logistic regression models were used to analyze medication adherence (Medication Possession Ratio (MPR) >80%), therapy persistence (gap of 60 days in treatment = discontinuation), any acute hypoglycemic event, and glycemic control (follow-up A1C levels = <7%). RESULTS: The final matched study included sample size of 3,263 subjects per cohort, average age was 65y (SD 4.9); 48% were female; 83% were enrolled in a commercial health plan. In the follow-up period, ExBiD patients experienced significantly fewer acute hypoglycemic events compared to IG patients (15 vs. 40; p < 0.001). Subjects in the ExBiD cohort were also more likely to obtain an MPR >80% (Odds Ratio (OR) = 1.93, CI 1.72-2.17), less likely to discontinue therapy (OR = 0.28, CI 0.25-0.31) and less likely to have any acute hypoglycemic event (OR = 0.48, CI 0.26-0.88) during the follow-up period. For those with valid A1C levels in both baseline and follow-up periods (N = 669, ExBiD vs. IG: 311 vs. 330), the IG subjects were more likely to achieve A1C <7% (ExBiD: 62%, CI 1.11-1.23) compared to IG subjects. Associated medical costs were similar for both groups. Results were comparable for patients >65y. CONCLUSIONS: Older ExBiD subjects were more likely to adhere to therapy and achieve A1C <7% and less likely to discontinue therapy or experience any acute hypoglycemic event than older IG subjects.

PDB2 EVALUATING ONE-YEAR STABILITY OF THE TOTAL ILLNESS BURDEN INDEX

Bilimkep F1, Cantrell R2, Greenfield S1, Kaplan S3
1University of California, Irvine, CA, USA, 2Eli Lilly and Company, Indianapolis, IN, USA

OBJECTIVES: The Total Illness Burden Index (TIBI) is a well-validated, patient-reported measure of the presence and severity of medical conditions comorbid to an index condition and is an important component of the Potential for Benefit Conceptual Model, shown to predict response to treatment in diabetes. The objective of this research was to determine the one-year stability of the TIBI. METHODS: We identified patients with type 2 diabetes enrolled in the Reducing Racial Disparities in Diabetes CoachEd Care (R2D2CC) study who had completed the 47-item TIBI at baseline and one year follow-up, and whose antihyperglycemic medication regimen was not altered during the study. t-tests and limits of agreement (LOA) were used to determine the change in TIBI score by ±2.5 points. RESULTS: The TIBI-47 was 90.0 ± 22.1 at baseline and 87.4 ± 20.6 at one year follow-up (p < 0.001). The observed change in TIBI score was 0.00 (SEM for the TIBI-47 was 0.90). Scores for patients with chronic heart failure, stroke, or diabetes, each with ±2.5 points LOA, were 0.48 ± 1.70, 0.00 ± 1.83, and 0.27 ± 1.86, respectively. CONCLUSIONS: TIBI scores appeared to be highly stable for this study sample over the one-year observation period. Small changes observed in symptom severity items may be due to effective clinical management. Further research is needed to distinguish observed differences due to treatment response from measurement error.

PDB3 LONG-TERM ANTIPROTEINURIC EFFECT OF ALISKIREN IN DIABETIC PATIENTS WITH PERSISTENT ALBUMINURIA DESPITE CHRONIC ACE OR ARB TREATMENT

Huang W1, Mersy J2, Levin F2
1Greater Baltimore Medical Center, Baltimore, MD, USA, 2Bay West Endocrinology Associates, Baltimore, MD, USA

OBJECTIVES: Studies showed dual blockade of renin-angiotensin-aldosterone system with ACEI and ARB had produced little gain with significant side effects in proteinuric patients. Here we evaluated the real-world effectiveness of long-term antiproteinuric effects of a novel dual blockade with the direct renin inhibitor aliskiren addition on chronic ACEI or ARB treatment in diabetic patients with persistent albuminuria. METHODS: We retrospectively collected data from the electronic database of Baywest Endocrinology Associates. Aliskiren150-300mg daily was added on chronic ACEI/ARB treatment (mean known duration 6y), and the Cockcroft-Gault formula was used to estimate the glomerular filtration rate (eGFR). The Wilcoxon Signed Ranks test and Kendall’s tau-b correlation analysis were used to calculate statistical significance. RESULTS: To 20y, mean follow-up 251.0, 251.1 and 251.2) within the index-treatment period and no hypoglycemia during the one-year pre-index period. The hypoglycemia cohort was more likely to receive insulin/sulfonylurea as index drug. The post-index A1c was numerically higher in the hypoglycemia cohort than control cohort (10.12 vs 9.87, p = 0.0602). The hypoglycemia cohort was more likely to develop CVD (HR = 1.32, 95%CI: 1.13-1.54) and 40% more likely to develop microvascular complications, compared with those without hypoglycemia. Risk of hypoglycemia was higher for the hypoglycemia cohort than control cohort (18.2% vs. 9.2%, 32.3% vs. 20.7%, both p-values < .0001, respectively). CONCLUSIONS: Patients with hypoglycemia may lead to worse clinical outcomes and higher risks of hospitalization and ER visit than those without.

PDB6 LONG-TERM EFFECTIVENESS OF MANAGING DIABETES WITH THE CHRONIC CARE MODEL: SIMULATIONS PERFORMED USING ARCHES

Zgibor JC1, Kuo S2, Schwartz CA3, Roberts MS4, Cohen MD5
1University of Pittsburgh, Pittsburgh, PA, USA, 2Archimedes, Inc., San Francisco, CA, USA

OBJECTIVES: Exenatide once-weekly (ExQW) is a GLP-1 receptor agonist that improves glycemia in patients with type 2 diabetes (T2DM) while eliciting potential weight loss and improvement in cardiovascular risk factors (blood pressure (BP) and plasma lipids). In published trials, ExQW resulted in superior reduction in A1C compared to maximum daily doses of sitagliptin and pioglitazone (Pio) on metformin (Met) background, and to titrated insulin glargine. METHODS: We used the Archimedes MedModel, a validated, clinically detailed model of physiology and healthcare delivery, to explore potential long-term ExQW benefits and costs. We simulated 20y of treatment in a virtual population (n = 19,885) based on individuals with T2DM drawn from NHANES who were on Met +/- nolullinonemurs (mean age 59y, BMI 33kg/m2, wt 93kg, duration T2DM 9y, baseline A1C 8%). The effects of three treatment regimens were modeled at simulation start: 1) advancement to insulin at A1C ≥8% (treat to target A1C <7%), 2) addition of Pio, and 3) addition of ExQW. ExQW’s effect on A1C, weight, and BP were derived from data from four phase 3 ExQW trials. Medical costs (inpatient, outpatient, ambulatory, treatments) were derived from the Medicare Current Beneficiary Survey, Medicare Part D data, drugstore.com, and published literature. Since ExQW is investigational, anti-diabetic therapy costs were excluded. RESULTS: At 20y, final mean A1C was 7% in all arms. Compared to insulin and Pio, respectively, ExQW was associated with relative reductions in final mean weight (5% vs both comparators), incidence of first Major Adverse Cardiovascular Events (9.2% vs. 9.1%), and hospitalization CHF (5.1% and 15%). All arms showed comparable benefit in controlling neuropathy, but ExQW showed significantly greater reductions in renal complications. As early as 5y, ExQW demonstrated total cost-savings of $545 and $839 per life-year vs insulin and insulin + Pio, respectively. CONCLUSIONS: These simulations suggest that the benefits of ExQW may translate into clinically and economically meaningful reductions in long-term outcomes.